While in severe asthma, type 2 inflammation may be relatively refractory to high dose ICS. It may respond to oral corticosteroids but their serious adverse effects mean that alternative treatments should be sought.1
Since type 2 inflammation is driven by cytokines, including IL-4, IL-5, and IL-13, the Global Initiative for Asthma (GINA) Guidelines recommends add-on type 2 biologic therapy for patients with exacerbations or poor symptom control on high-dose ICS/LABA who have the following criteria of type 2 inflammation:1
Consider if an add-on biologic targeting the type 2 inflammation pathway would be beneficial.
A range of biologic agents are now registered in Australia to treat severe asthma, targeting different components of type 2 inflammation.2-5 Clinicians will need weigh up the patient’s characteristics and available clinical data when making treatment decisions.
Eligibility criteria and predictors of good response for various biologic therapies.2-5
Adapted from the Global Initiative for Asthma (GINA). Difficult-to-treat & severe asthma in adolescent and adult patients: diagnosis and management. A GINA pocket guide for health professionals, V2.0 April 2019.
*Not registered In Australia for nasal polyposis